Pilot Study on QTc Interval in Dogs Treated with Domperidone.

Area of Science:

• Veterinary Pharmacology
• Cardiology
• Infectious Diseases

Background:

• Domperidone is an immunomodulatory drug for canine leishmaniosis.
• Human studies report pro-arrhythmic side effects linked to domperidone via QT interval prolongation.
• The cardiac safety of domperidone in dogs requires evaluation.

Purpose of the Study:

• To evaluate the corrected QT (QTc) interval in dogs receiving domperidone for leishmaniosis.
• To assess domperidone's impact on cardiac function and electrolyte balance in dogs.

Main Methods:

• Pilot study involving 17 dogs treated with domperidone for four weeks.
• Electrocardiograms and blood analyses (creatinine, urea nitrogen, electrolytes) were performed before and after treatment.
• Two dogs underwent intensive QTc monitoring after a single dose.

Main Results:

• A significant increase in QTc interval and chloride concentrations was observed post-treatment.
• QTc values slightly exceeded the upper limit in only one dog; chloride levels remained normal.
• Creatinine concentrations significantly decreased, and QTc values were normal in the intensive monitoring group.

Conclusions:

• Domperidone administration resulted in a slight QTc interval prolongation in dogs.
• Further studies are recommended to assess cardiac risks in susceptible canine populations and those on interacting medications.